Skip to main content
Contact Us
Subscribe
E-Edition
73°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024
October 31, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AVIR
Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
October 30, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AVIR
Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19
September 13, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AVIR
Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation Pathway
August 28, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AVIR
Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
August 07, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AVIR
Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024
July 31, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AVIR
Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024
June 05, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AVIR
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
May 29, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AVIR
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024
May 22, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AVIR
Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AVIR
Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024
May 07, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AVIR
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
April 29, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AVIR
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
March 27, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AVIR
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 28, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AVIR
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
February 21, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AVIR
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19
January 08, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AVIR
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AVIR
Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
November 13, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AVIR
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
November 08, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AVIR
Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences
November 08, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AVIR
Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
November 02, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AVIR
Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023
November 01, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AVIR
Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
September 06, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AVIR
Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
August 08, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AVIR
Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
August 01, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AVIR
Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination
June 15, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AVIR
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
June 05, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AVIR
Atea Pharmaceuticals’ Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences
May 30, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AVIR
Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences
May 23, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AVIR
Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
May 08, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AVIR
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.